Open Journal Systems

Tenosynovial Giant Cell Tumor: Better molecular understanding revolutionizes treatment outcome

Emad Shash ()


Tenosynovial giant cell tumors (TGCTs) are rare tumors, which are primarily treated via surgery with a low likelihood of metastasis. Although wide excision is an excellent choice for local control, tumors located within or close to major joints, along with the benign nature of the disease, make such resection impractical. An increase in local recurrences and the need for multiple surgical procedures promoted the interest in targeted-therapies for this disease. TGCTs contain a mixture of giant cells, mononuclear cells and inflammatory cells, with clonal cytogenetic abnormalities through rearrangements involving 1p11–13. Colony stimulating factor (CSF1) gene encodes for the ligand of CSF1 receptor (CSF1R). The CSF1 gene is located at the chromosome 1p13 breakpoint and is found to be translocated in 63%–77% of patients with TGCTs. Selective CSF1R inhibitors yield high response rate and disease control, demonstrating the integration of a new drug development technology that could revolutionize treatment outcomes.  


Tenosynovial giant cell tumor; colony stimulating factor receptor

Full Text:



Jaffe HL, Lichtenstein L, Sutro CJ. Pigmented villonodular synovitis, bursitis and tenosynovitis. Arch Pathol 1941; 31(3): 731–765.

Lucas DR. Tenosynovial giant cell tumor: Case report and review. Arch Pathol Lab Med 2012; 136(8): 901–906. doi: 10.5858/arpa.2012-0165-CR.

Weiss SW, Goldblum JR. Benign tumors and tumor-like lesions of synovial tissue. In: Enzinger and Weiss’s soft tissue tumors. 5th ed. Philadelphia: Mosby Elsevier; 2008. p. 769.

Dal Cin P, Sciot R, Samson I, De Smet L, De Wever I, Van Damme B, Van Den Berghe H. Cytogenetic characterization of tenosynovial giant cell tumors (nodular tenosynovitis). Cancer Res 1994; 54: 3986–3987.

West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Hunstman D, van de Rijn M. A landscape effect in tenosynovial giant cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103(3): 690–695. doi: 10.1073/pnas.0507321103.

Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol 2011; 23(4): 361–366. doi: 10.1097/CCO.0b013e328347e1e3.

Brandal P, Bjerkehagen B, Heim S. Molecular cytogenetic characterization of tenosynovial giant cell tumors. Neoplasia 2004; 6(5): 578–583. doi: 10.1593/neo.04202.

Nilsson M, Höglund M, Panagopoulos I, Sciot R, Dal Cin P, Debiec-Rychter M, Mertens F, Mandahl N. Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors. Virchows Arch 2002; 441(5): 475–480. doi: 10.1007/s00428-002-0640-y.

Sciot R, Rosai J, Dal Cin P, de Wever I, Fletcher CD, Mandahl N, Mertens F, Mitelman F, Rydholm A, Tallini G, van de Berghe H, Vanni R, Willén H. Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: A report from the Chromosomes and Morphology (CHAMP) study group. Mod Pathol 1999; 12(6): 576–579.

Blay JY, El Sayadi H, Thiesse P, Garret J, Ray-Coquard. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19(4): 821–822. doi: 10.1093/annonc/mdn033.

Ravi V, Wang W, Araujo DM, Ludwig JA, Luke RJ, Lewis VO, Trent JC, Benjamin RS, Patel S. Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. J Clin Oncol 2010; 28(15s): 10011.

Cassier PA, Stacchiotti S, Gelderblom H, Thomas DM, Van Der Graaf W, Seddon BM, Julien D, Wagner AJ, Blay J. Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). J Clin Oncol 2010; 28(15s): 10012.

Chabner B, Richon V. Structural Approaches to Cancer Drug Development. N Engl J Med 2015; 373: 402–403. doi: 10.1056/NEJMp1503567.

Zhang C, Ibrahim PN, Zhang J, Burton EA, Habets G, Zhang Y, Powell B, West BL, Matusow B, Tsang G, Shellooe R, Carias H, Nguyen H, Marimuthu A, Zhang KYJ, Oh A, Bremer R, Hurt CR, Artis DR, Wu G, Nespi M, Spevak W, Lin P, Nolop K, Hirth P, Tesch GH, Bollag G. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci USA 2013; 110(14): 5689–5694. doi: 10.1073/pnas.1219457110.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 2015; 373: 428–437. doi: 10.1056/NEJMoa1411366.



  • There are currently no refbacks.

Copyright (c) 2018 Emad Shash

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.